Status:
COMPLETED
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborating Sponsors:
Molecular NeuroImaging
Conditions:
Parkinsonian Syndrome
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parki...
Detailed Description
* Subjects will be referred to the Institute for Neurodegenerative Disorders (IND) by practicing general neurologists with genuine uncertainty regarding the subject's diagnosis. * Subjects with suspec...
Eligibility Criteria
Inclusion
- Age \>21
- Any parkinsonian or extrapyramidal symptoms
- Parkinsonian symptoms for \< 2 years duration.
- No significant abnormalities on screening laboratory studies including: CBC, Chem-20 and urinalysis.
- Willingness to comply with study protocol.
Exclusion
- Pregnancy
- Significant medical disease including abnormalities on screening biochemical or hematological labs or abnormal electrocardiogram (ECG).
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
169 Patients enrolled
Trial Details
Trial ID
NCT00129675
Start Date
February 1 2003
End Date
May 1 2009
Last Update
July 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510